microdosing semaglutide side effects People are 'microdosing' weight-loss drugs. A GP explains what to watch out for GLP-1 microdosing is popular, but

Advise patients who are exposed to WEGOVY during pregnancy to contact Novo Nordisk at 1-877-390-2760 or www.wegovypregnancyregistry.com [see Use in Specific Populations (8.1)]

WSHU: And hovering over all of this is the federal cuts to Medicaid that are being considered right now

Dulaglutide shows nausea rates of approximately 8-12% at lower doses, whilst semaglutide (Wegovy) demonstrates rates around 44% in weight management trials

With access to compounded semaglutide now highly restricted, FDA-approved GLP-1 therapies remain the standard of care for most patients

The FDA-approved GLP-1 RA landscape encompasses single-agonists and the dual GIP/GLP-1 agonist tirzepatide